Physician profile
Anas Khouri
NPI 1699345603
$2,400.07
in general payments reported to CMS, 2019-2025
17 companies · $1,365 in 2025
The $1,365 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $145 · 2024: $891 · 2025: $1,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,400.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $623.07 | 2024-2025 | |
| Janssen Biotech, INC. | $421.39 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $312.91 | 2023-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $161.46 | 2024-2025 | Ibsrela |
| Gilead Sciences, INC. | $122.11 | 2023 | Veklury |
| Aimmune Therapeutics, INC. | $107.73 | 2025 | Zenpep, Vowst |
| Regeneron Healthcare Solutions, INC. | $101.25 | 2025 | Dupixent |
| Mirum Pharmaceuticals, INC. | $100.26 | 2025 | Livmarli |
| Janssen Scientific Affairs, LLC | $100.12 | 2024 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.17 | 2024-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $69.41 | 2025 | Rezdiffra |
| Erbe USA INC | $65.00 | 2025 | Vio3 |
| Mallinckrodt Hospital Products INC. | $35.19 | 2024 | Acthar |
| Celltrion USA INC. | $28.81 | 2025 | Vegzelma |
| Astrazeneca Pharmaceuticals LP | $26.14 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $24.87 | 2024 | Tavneos |
| Pfizer INC. | $24.18 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anas Khouri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.